156 related articles for article (PubMed ID: 26885610)
1. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
Min SJ; Jang HJ; Kim JH
Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
[TBL] [Abstract][Full Text] [Related]
4. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis.
Kim JH; Min SJ; Jang HJ; Cho JW; Kim SH; Kim HS
J Cancer; 2015; 6(4):387-93. PubMed ID: 25767610
[TBL] [Abstract][Full Text] [Related]
5. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.
Jang HJ; Kim BC; Kim HS; Kim JH; Song HH; Kim JB; Park JJ; Yoon SN; Woo JY; Zang DY
Oncology; 2014; 86(2):117-21. PubMed ID: 24480800
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the EORTC criteria and PERCIST in solid tumors: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Sep; 7(36):58105-58110. PubMed ID: 27517621
[TBL] [Abstract][Full Text] [Related]
9. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Yang I
Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
[TBL] [Abstract][Full Text] [Related]
10. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S; Isaac G; De Vries EGE; Bogaerts J; Chen A; Dancey J; Ford R; Gwyther S; Hoekstra O; Huang E; Lin N; Liu Y; Mandrekar S; Schwartz LH; Shankar L; Therasse P; Seymour L;
J Clin Oncol; 2019 May; 37(13):1102-1110. PubMed ID: 30860949
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
[TBL] [Abstract][Full Text] [Related]
12. Comparing RECIST with EORTC criteria in metastatic bladder cancer.
Öztürk H
J Cancer Res Clin Oncol; 2016 Jan; 142(1):187-94. PubMed ID: 26208817
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
Kim HD; Kim BJ; Kim HS; Kim JH
Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
Zhou T; Zheng L; Hu Z; Zhang Y; Fang W; Zhao Y; Ge J; Zhao H; Zhang L
Sci Rep; 2015 Jan; 5():7683. PubMed ID: 25567662
[TBL] [Abstract][Full Text] [Related]
15. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy.
Sudarski S; Shi J; Schmid-Bindert G; Manegold C; Pilz LR; Zhou C; Schoenberg SO; Henzler T
J Thorac Oncol; 2015 Jan; 10(1):164-71. PubMed ID: 25247342
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
[TBL] [Abstract][Full Text] [Related]
17. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Kanazu M; Maruyama K; Ando M; Asami K; Ishii M; Uehira K; Minomo S; Matsuda Y; Kawaguchi T; Atagi S; Ogawa Y; Kusunoki Y; Takada M; Kubo A
Clin Lung Cancer; 2014 May; 15(3):182-7. PubMed ID: 24518101
[TBL] [Abstract][Full Text] [Related]
18. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
[TBL] [Abstract][Full Text] [Related]
19. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA; Weeber F; Bins S; Gadellaa-van Hooijdonk CG; van Werkhoven E; Willems SM; van Stralen M; Veldhuis WB; Ubink I; Steeghs N; de Jonge MJ; Langenberg MH; Schellens JH; Sleijfer S; Lolkema MP; Voest EE
Ann Oncol; 2016 Aug; 27(8):1638-43. PubMed ID: 27234642
[TBL] [Abstract][Full Text] [Related]
20. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
